What is the next earnings date for BCT stock?
BRIACELL THERAPEUTICS CORP (BCT.CA) will report earnings on 2026-06-15.
BRIACELL THERAPEUTICS CORP (BCT.CA) Forecast, Price Target & Analyst Ratings
TSX:BCT • CA1079303071
Current stock price
5.62 CAD
-0.24 (-4.1%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BRIACELL THERAPEUTICS CORP (BCT.CA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Jun 15, 2026
- Period
- Q3 / 2026
- EPS Estimate
- -$2.77
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of CA$5.62 to mean target of N/A, Based on 5 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
BCT.CA was analyzed by 5 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about BCT.CA.
In the previous month the buy percentage consensus was at a similar level.
Only 5 analysts analyzed BCT.CA. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Jun 15, 2026
- Period
- Q3 / 2026
- EPS Estimate
- -$2.77
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 83.13%
- Number of Analysts
- 2
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
BCT.CA is expected to report earnings on 6/15/2026. The consensus EPS estimate for the next earnings is -2.77 CAD and the consensus revenue estimate is 0 CAD.
Full Analyst Estimates 2026 - 2029
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 380.95% | N/A | N/A | ||||||||||||
| EBITDA YoY % growth | N/A | -1.688M | -2.344M -38.90% | -3.613M -54.12% | -4.519M -25.08% | -3.547M 21.50% | -6.961M -96.22% | -15.274M -119.43% | -23.257M -52.27% | -33.246M -42.95% | -27.098M 18.49% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -3.548M | -1.689M 52.41% | -2.345M -38.83% | -3.625M -54.63% | -4.533M -25.04% | -3.561M 21.44% | -6.976M -95.89% | -15.289M -119.16% | -23.272M -52.22% | -33.33M -43.22% | -27.205M 18.38% | N/A -25.11% | N/A -27.89% | N/A | N/A | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -195.00 -26.19% | -45.00 76.92% | -128.19 -184.87% | N/A 90.98% | N/A 70.31% | N/A 54.12% | N/A 52.56% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 26 | |
|---|---|
| EPS Q2Q % growth | -2.77 83.13% |
| Revenue Q2Q % growth | |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -9.393M -48.43% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.73%
EPS Next 5 Year
18.83%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
BRIACELL THERAPEUTICS CORP / BCT.CA Forecast FAQ
Can you provide the consensus estimates for BRIACELL THERAPEUTICS CORP next earnings?
The consensus EPS estimate for the next earnings of BRIACELL THERAPEUTICS CORP (BCT.CA) is -2.77 CAD and the consensus revenue estimate is 0 CAD.